Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Vistagen Therapeutics, Inc. common stock during the specified Class Period from April 1, 2024, to December 16, 2025, with a lead plaintiff deadline of March 16, 2026 [1] Group 1: Class Action Details - Investors who purchased Vistagen common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][7] - Investors wishing to serve as lead plaintiff must file a motion with the Court by March 16, 2026 [3] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4] - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been recognized as a leader in the field of securities class actions [4] Group 3: Case Background - The lawsuit alleges that Vistagen's defendants provided misleading information regarding the development and commercialization of its drug fasedienol, which is intended for the treatment of social anxiety disorder [5] - Defendants reportedly made positive assertions about fasedienol's trial success while concealing material adverse facts about the Phase 3 PALISADE-3 trial, leading to investor damages when the truth was revealed [6]

Core Viewpoint - A class action lawsuit has been filed against Vistagen Therapeutics, Inc. for allegedly providing misleading information regarding its Phase 3 PALISADE-3 trial of fasedienol, leading to significant investor losses [2][8]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Vistagen common stock between April 1, 2024, and December 16, 2025, inclusive [2]. - Investors have until March 16, 2026, to apply to the Court to be appointed as lead plaintiff in the lawsuit [2]. Group 2: Allegations - The complaint alleges that Vistagen made overwhelmingly positive statements while concealing material adverse facts about the Phase 3 PALISADE-3 trial [8]. - On December 17, 2025, Vistagen announced that the PALISADE-3 study did not show a statistically significant improvement on its primary endpoint, leading to a dramatic stock price decline [8]. Group 3: Financial Impact - Following the announcement of the trial results, Vistagen's stock price fell from $4.36 per share on December 16, 2025, to $0.86 per share on December 17, 2025, representing a decline of more than 80% [8].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered In Vistagen To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Vistagen between April 1, 2024 and December 16, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Jan. 24, 2026 (GLOBE NEWSWIRE) -- Faruqi & Far ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Vistagen Therapeutics, Inc. due to alleged violations of federal securities laws related to misleading statements about its Phase 3 PALISADE-3 trial of fasedienol for social anxiety disorder [2][5]. Group 1: Legal Investigation - The law firm is encouraging investors who purchased Vistagen securities between April 1, 2024, and December 16, 2025, to discuss their legal rights [1]. - A federal securities class action has been filed against Vistagen, with a deadline of March 16, 2026, for investors to seek the role of lead plaintiff [2][7]. - The firm has a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4]. Group 2: Trial Results and Stock Impact - On December 17, 2025, Vistagen announced that its PALISADE-3 study did not meet its primary efficacy endpoint, resulting in a significant stock decline of $3.50 or 80.27%, closing at $0.86 [6]. - The study failed to show statistically significant improvement in anxiety reduction compared to placebo, raising concerns about the company's disclosures [5][6]. Group 3: Call for Information - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Vistagen's conduct [8].

Core Viewpoint - A class action lawsuit has been announced by Rosen Law Firm on behalf of purchasers of Vistagen Therapeutics, Inc. common stock during the specified Class Period from April 1, 2024, to December 16, 2025, with a lead plaintiff deadline of March 16, 2026 [1]. Group 1: Lawsuit Details - The lawsuit claims that Vistagen provided misleading information regarding its drug fasedienol, which is under development for treating social anxiety disorder, while making overly positive assertions about its trial success based on previous results [5][6]. - Defendants allegedly concealed material adverse facts about the Phase 3 PALISADE-3 trial, leading to investor damages when the true information became public [6]. Group 2: Participation Information - Investors who purchased Vistagen common stock during the Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][7].

NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Vistagen Therapeutics, Inc. (NASDAQ: VTGN) between April 1, 2024 and December 16, 2025, both dates inclusive (the “Class Period”), of the important March 16, 2026 lead plaintiff deadline. SO WHAT: If you purchased Vistagen common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fe ...

Core Viewpoint - Vistagen Therapeutics, Inc. is facing a class action securities lawsuit due to alleged securities fraud related to its Phase 3 PALISADE-3 trial of fasedienol, which did not meet its primary endpoint, leading to a significant stock price decline of over 80% [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors affected by alleged securities fraud between April 1, 2024, and December 16, 2025 [1]. - Defendants reportedly made positive statements while concealing adverse facts about the Phase 3 PALISADE-3 trial of fasedienol, which is intended for treating social anxiety disorder [2]. - Following the announcement that the trial did not show statistically significant improvement, Vistagen's stock plummeted from $4.36 to $0.86 per share, marking a decline of more than 80% [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until March 16, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a strong track record, having secured hundreds of millions for shareholders and being recognized as one of the top securities litigation firms in the U.S. for seven consecutive years [4].

Core Viewpoint - A class action lawsuit has been filed against Vistagen Therapeutics, Inc. for allegedly providing misleading information regarding its drug fasedienol during the Class Period from April 1, 2024, to December 16, 2025 [1][5][6] Group 1: Lawsuit Details - The lawsuit claims that Vistagen made positive assertions about the success of fasedienol based on prior clinical trial results, while concealing material adverse facts about the Phase 3 PALISADE-3 trial [5][6] - Investors who purchased Vistagen common stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2][3] Group 2: Legal Representation - The Rosen Law Firm, which is leading the class action, has a strong track record in securities class actions, having achieved significant settlements for investors, including over $438 million in 2019 [4] - Investors are encouraged to select qualified legal counsel with a proven history in leadership roles within class action lawsuits [4] Group 3: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly [3][7] - A lead plaintiff must be appointed by March 16, 2026, to represent the interests of other class members [1][3]

Core Viewpoint - Bernstein Liebhard LLP is reminding investors of Vistagen Therapeutics, Inc. about a deadline related to a securities fraud class action lawsuit against the company [1]. Group 1: Lawsuit Details - A class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of investors who purchased Vistagen common stock between April 1, 2024, and December 16, 2025, alleging violations of the Securities Exchange Act of 1934 [3]. - The lawsuit claims that the defendants made misrepresentations regarding the Company's Phase 3 PALISADE-3 trial study of fasedienol, which is being developed for the acute treatment of social anxiety disorder [4]. Group 2: Legal Participation - Investors wishing to serve as lead plaintiff for the class must file papers by March 16, 2026, with the role involving directing the litigation on behalf of other class members [5]. - Participation as a lead plaintiff is not required to share in any potential recovery, and all representation is on a contingency fee basis, meaning shareholders incur no fees or expenses [5]. Group 3: Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for its clients since 1993 and has represented both individual investors and large public and private pension funds [6]. - The firm has been recognized for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for sixteen consecutive years [6].

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose material adverse facts concerning its Phase 3 PALISADE-3 trial study of fasedienol, an ...